Drugs / SC262
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06285422 | Apr 2024 → Dec 2025 overdue | large B-cell lymphoma, non-Hodgkin lymphoma | Sana Biotechnology | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC262 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06285422 ↗ |
| Route | Intravenous | “SC262 administered intravenously (IV)” NCT06285422 ↗ |